Merck & Company Inc (MRK)vsAlaunos Therapeutics Inc (TCRT)
MRK
Merck & Company Inc
$149.32
+0.40%
HEALTHCARE · Cap: $365.34B
TCRT
Alaunos Therapeutics Inc
$0.96
-5.83%
HEALTHCARE · Cap: $3.05M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2218966533% more annual revenue ($66.57B vs $3,000). MRK leads profitability with a 4.8% profit margin vs 0.0%. TCRT appears more attractively valued with a PEG of 0.58. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
TCRT
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.2%
Fair Value
$83.04
Current Price
$149.32
$66.28 premium
Intrinsic value data unavailable for TCRT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Growing faster than its price suggests
Areas to Watch
Trading at 8.8x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : TCRT
The strongest argument for TCRT centers on PEG Ratio. PEG of 0.58 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : TCRT
The primary concerns for TCRT are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK carries more volatility with a beta of 0.23 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (36/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Alaunos Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?